Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma.

Trial Profile

Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2015

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Nov 2011 Actual patient number is 5 as reported by ClinicalTrials.gov.
    • 23 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top